Regulatory Milestone
The US Food and Drug Administration (USFDA) has accepted the Biologics License Application (BLA) for FYB206 for review. This represents the first publicly announced acceptance by the USFDA of a filing for a proposed biosimilar to Keytruda® (pembrolizumab). The BLA was submitted in the third quarter of 2026.
Under the Biosimilar User Fee Amendments (BsUFA), the USFDA aims to complete its review within twelve months of submission, comprising up to 60 days for the filing review and 10 months for the substantive review. Based on this timeline, a decision could be expected in the third quarter of 2027. The regulatory dossier for FYB206 has also been submitted to Health Canada.
Development Pathway
FYB206 was developed without a comparative Phase III efficacy trial, following a development pathway agreed upon with the USFDA in early 2025 (specifically February 2025). This development approach enabled acceleration of the program and substantial reduction in development investment while maintaining rigorous scientific standards required for biosimilar approval.
Commercialization Rights
Zydus holds exclusive commercialization rights for FYB206 in the United States and Canada. Zydus brings extensive commercial experience in the North American market for this product. Formycon is responsible for completing development, preparing and filing the regulatory dossiers, and supplying the product.
With the USFDA's acceptance of the BLA for review, Formycon has reached a regulatory milestone under the agreement that entitles it to a milestone payment from Zydus. Zydus will commercialize FYB206 in both markets, subject to regulatory approval and resolution of any intellectual property issues. Formycon holds the global rights to FYB206 and will participate in the gross profits of its commercialization partners.
Market Context
Pembrolizumab is an immune checkpoint inhibitor that binds to and blocks the PD-1 receptor and is used to treat numerous types of cancer. In 2025, worldwide sales of Keytruda®, including the subcutaneous formulation Keytruda Qlex™, reached USD 31.7 billion. In the first half of 2026, combined sales of Keytruda® and Keytruda Qlex™ totaled USD 16.40 billion. Keytruda® remains the world's bestselling biologic medicine.
Partnership Background
In December 2025, Formycon and Zydus entered into an exclusive licensing and supply agreement for FYB206 in the United States and Canada.
Management Commentary
Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, stated: "Acceptance of the application marks a significant step toward expanding access to affordable pembrolizumab therapy in the U.S. and Canada. As demand for high-quality, accessible oncology treatments continues to rise, FYB206 has the potential to improve patient access and outcomes while strengthening our oncology biosimilars portfolio."
Dr. Stefan Glombitza, CEO of Formycon AG, stated: "With the FDA's acceptance of the FYB206 application for review, we are among the very first companies to advance a biosimilar to the world's bestselling biologic medicine to this stage. We developed FYB206 on a path agreed with the FDA, without conducting a comparative Phase III efficacy trial."
Disclaimer
FYB206 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed.